Exagen Inc. (XGN) Stock Forecast
XGN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 7 analysts
- Price target
- $10.29 average of analyst targets
- Upside to target
- +33.2% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.19
- 52-week range
- $2.65 – $11.96
XGN analyst ratings
7 analystsNumber of analysts at each rating.
XGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.18 | −$0.16 | −$0.31 | +45.2% | 2 |
| Current fiscal year (2026) | −$0.63 | −$0.63 | −$0.63 | −$0.84 | +25.2% | 2 |
| Next fiscal year (2027) | −$0.47 | −$0.53 | −$0.41 | −$0.63 | +25.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $18.3M | $18.0M | $18.7M | +6.4% | 7 |
| Current fiscal year (2026) | $73.9M | $73.5M | $74.7M | +11.0% | 7 |
| Next fiscal year (2027) | $81.5M | $80.7M | $82.5M | +10.3% | 7 |
XGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XGN revenue: reported and forecast
XGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.17 | −$0.17 | −$0.17 | −$0.17 | +17.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.63 | −$0.62 | −$0.62 | −$0.62 | −$0.63 | 0.0% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.43 | −$0.44 | −$0.47 | −$0.47 | −$0.47 | +9.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XGN beat in 9 of 12.
What analysts expect from XGN
7 analysts cover Exagen; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.29, 33.2% above the latest close of $7.72. Analysts expect earnings of −$0.63 per share for 2026, +25.2% from a year earlier. For 2027 the average estimate is −$0.47 per share on revenue of $81.5 million. Exagen beat the EPS estimate in 9 of the last 12 quarters.
Related: XGN income statement, XGN key metrics, XGN chart. See the XGN stock overview for the latest quote and news.
XGN forecast FAQ
What is Exagen's price target?
The average analyst price target for Exagen is $10.29, 33.2% above the latest close of $7.72.
Is Exagen a buy, hold or sell?
Of 7 analysts covering Exagen, 7 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Exagen's EPS forecast?
Analysts forecast −$0.63 per share for 2026 (range −$0.63 to −$0.63); for 2027 the estimate is −$0.47.
What is Exagen's revenue forecast?
The average revenue estimate for 2026 is $73.9 million, growth of 11.0%; for 2027 it is $81.5 million.
When does Exagen report earnings?
Exagen is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.19.
Does Exagen usually beat earnings estimates?
Exagen reported EPS at or above the analyst estimate in 9 of the last 12 quarters.